Pfizer is in talks with the Indian government seeking an “expedited approval pathway” for its COVID-19 vaccine, its CEO Albert Bourla said on LinkedIn on Monday.

Bourla announced a donation of medicines worth more than $70 million.

“Unfortunately, our vaccine is not registered in India although our application was submitted months ago,” he said.

“We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country.”